Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 49

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 49
---
’ control such as new regulatory requirements or changes to existing regulatory requirements (or feedback from regulatory authorities that requires Longevity to modify the design of its clinical trials) and changes in the market for biotechnology generally. The FutureTech Board considered that the failure of any of these activities to be completed successfully may decrease the actual benefits of the Business Combination and that FutureTech stockholders may not fully realize these benefits to the extent that they expected following the completion of the Business Combination. For additional description of these risks, please see the section entitled “Risk Factors;”

Competition. Longevity’s industry are rapidly evolving and Longevity will face competitions from a variety of companies in the same industry.

Business Plan and Projections May Not be Achieved. The risk that Longevity may not be able to execute on its business plan on time or at all, or realize the financial performance as set forth in the financial projections presented to FutureTech’s management and board, and the risk that Longevity may need to raise additional capital to achieve its business plan.

Limitations of Review. The fact that FutureTech’s management, board and advisors reviewed only certain materials in connection with their due diligence review of Longevity and Targets and may not have properly evaluated Longevity’s and Targets’ business.

Liquidation. The risks and costs to FutureTech if the Business Combination is not completed, including the risk of diverting management focus and resources from other business combination opportunities, which could result in FutureTech being unable to effect a business combination within the completion window which would require FutureTech to liquidate.

Shareholder Vote and Other Actions. The risk that FutureTech Stockholders may object to and challenge the Business Combination and take action that may prevent or delay the Closing.

Closing Conditions.The fact that completion of the Business Combination is conditioned on the satisfaction of certain closing conditions that are not within FutureTech’s control.

Litigation. The possibility of litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination.

Fees and Expenses. The fees and expenses associated with completing the Business Combination.

Exercise of Redemption Rights by Public Stockholders. The risk that some or all holders of public shares would exercise their redemption rights, thereby depleting the amount of cash available to Longevity following the Closing.

| 8 |

Nasdaq Listing. The potential inability to list post-combination company’s securities on Nasdaq or maintain such listing following the Closing.

Interests of Certain Persons. FutureTech’s officers and directors may have